Skip to main content

Table 1 Patient characteristics

From: Obstructive sleep apnoea accelerates FEV1 decline in asthmatic patients

Characteristics No OSA Mild-to-Moderate OSA Severe OSA p value
n = 10 n = 33 n = 34
Age 49.0 ± 13.6 60.0 ± 13.3 62.9 ± 12.7 0.021
Male, n (%) 6 (60) 25 (75.8) 20 (58.8) 0.348
BMI 23.4 ± 4.0 24.8 ± 4.3 29.7 ± 4.7 0.001
Current Smoker, n (%) 2 (20.0) 10 (30.3) 12 (35.3) 0.653
Pulmonary function Test (1st year)
 FEV1/FVC 71.9 ± 13.2 73.2 ± 18.9 79.1 ± 13.9 0.078
 FEV1, Litre 2.12 ± 0.44 1.75 ± 0.82 1.91 ± 0.80 0.400
 FEV1 (% predicted) 68.6 ± 15.9 65.3 ± 24.6 77.1 ± 25.3 0.132
 FVC, Litre 2.94 ± 0.42 2.39 ± 0.83 2.41 ± 0.84 0.096
Decline of FEV1/year, (% from baseline) 1.3 ± 1.3 3.1 ± 3.3 4.3 ± 3.4 0.024
Decline of FEV1/year, (% predicted) 0.0 ± 1.1 1.0 ± 1.9 2.3 ± 3.0 0.027
Decline of FEV1/year (mL) 24.3 ± 27.5 41.9 ± 45.3 72.4 ± 61.7 0.046
Decline of FVC/year, (% from baseline) 1.1 ± 3.6 1.4 ± 3.4 2.6 ± 3.6 0.499
Decline of FVC/year, (% predicted) 0.6 ± 3.4 0.8 ± 2.6 1.6 ± 2.9 0.608
Decline of FVC/year, (mL) 32.5 ± 111.1 39.9 ± 84.4 54.9 ± 76.1 0.735
ER visit, n/year 0.11 ± 0.14 0.48 ± 0.63 0.52 ± 0.62 0.256
Medication
 Inhaled glucocorticoid 9 (90) 33 (100) 31 (91.2) 0.208
 Inhaled long-acting beta-agonist 6 (60) 25 (75.8) 30 (88.2) 0.128
 Leukotriene antagonist 1 (10) 10 (30.3) 21 (61.8) 0.003
  1. Data are presented as mean ± SEM, or number (percentage)
  2. Abbreviations: OSA obstructive sleep apnoea, BMI body mass index, FEV 1 forced expiratory volume in 1 second, FVC forced volume capacity, ER emergency department